Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of microRNA-155, which is in Phase I clinical trial for treating cutaneous T-cell lymphoma; MRG-201, a replacement for microRNA-29, which is in Phase I clinical trial that is found at low levels in various pathological fibrotic conditions, including cutaneous, cardiac, renal, hepatic, and pulmonary fibrosis, as well as systemic sclerosis; and MRG-110, an inhibitor of microRNA-92 that is expressed in endothelial cells and has shown to accelerate the formation of new blood vessels in preclinical models of heart failure, peripheral ischemia, and dermal wounding in the United States and Japan. The company also develops MRG-107, an inhibitor of miR-155 for treating neuronal amyotrophic lateral sclerosis, and other neurodegenerative indications, including spinal cord injury. It also develops preclinical product candidates for treating various indications, including oncology, visual pathologies, neurodegeneration, and hearing loss. Miragen Therapeutics, Inc. has a collaboration agreement with Les Laboratoires Servier and Institut de Recherches Servier for the development of MRG-110. The company was founded in 2006 and is based in Boulder, Colorado.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MGEN
CUSIPN/A
Phone720-643-5200
Debt
Debt-to-Equity Ratio0.14
Current Ratio20.91
Quick Ratio20.91
Price-To-Earnings
Trailing P/E Ratio-5.19
Forward P/E Ratio-6.75
P/E GrowthN/A
Sales & Book Value
Annual Sales$4 million
Price / Sales54.04
Cash FlowN/A
Price / CashN/A
Book Value$1.73 per share
Price / Book4.14
Profitability
EPS (Most Recent Fiscal Year)($1.38)
Net Income$-26,510,000.00
Net Margins-290.61%
Return on Equity-50.53%
Return on Assets-40.91%
Miscellaneous
Employees65
Outstanding Shares30,190,000
Market Cap$221.61
Miragen Therapeutics (NASDAQ:MGEN) Frequently Asked Questions
What is Miragen Therapeutics' stock symbol?
Miragen Therapeutics trades on the NASDAQ under the ticker symbol "MGEN."
How were Miragen Therapeutics' earnings last quarter?
Miragen Therapeutics Inc (NASDAQ:MGEN) released its quarterly earnings data on Wednesday, May, 9th. The medical research company reported ($0.18) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.25) by $0.07. The medical research company earned $4.78 million during the quarter, compared to analysts' expectations of $1.17 million. Miragen Therapeutics had a negative net margin of 290.61% and a negative return on equity of 50.53%. View Miragen Therapeutics' Earnings History.
What price target have analysts set for MGEN?
9 analysts have issued twelve-month target prices for Miragen Therapeutics' shares. Their predictions range from $13.00 to $29.00. On average, they anticipate Miragen Therapeutics' share price to reach $17.9375 in the next twelve months. This suggests a possible upside of 150.5% from the stock's current price. View Analyst Ratings for Miragen Therapeutics.
What is the consensus analysts' recommendation for Miragen Therapeutics?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Miragen Therapeutics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Miragen Therapeutics stock?
Here are some recent quotes from research analysts about Miragen Therapeutics stock:
- 1. According to Zacks Investment Research, "Miragen Therapeutics, Inc. is a biopharmaceutical company. It develops microRNA biology, oligonucleotide chemistry, drugs and therapies for cancer, pathologic fibrosis, neuro-inflammatory and cardiovascular diseases. Miragen Therapeutics, Inc., formerly known as Signal Genetics, is headquartered in Boulder, Colorado. " (7/18/2018)
- 2. Cann analysts commented, "We cover miRagen Therapeutics with an Outperform rating and are increasing our price target to account for an increased average forward price-to-sales multiple of the biotechnology sector." (7/9/2018)
- 3. Wedbush analysts commented, "Athersys announced an expanded agreement with Helios KK (6927JP – NR) that includes additional indications and will bring in an additional $20M in capital to Athersys. In association with this deal, Dr. Hardy Kagimoto, CEO of Helios has been nominated for election (June 18, 2018) to the Athersys board of directors." (6/7/2018)
Are investors shorting Miragen Therapeutics?
Miragen Therapeutics saw a increase in short interest in June. As of June 29th, there was short interest totalling 1,179,487 shares, an increase of 77.9% from the June 15th total of 663,054 shares. Based on an average trading volume of 269,772 shares, the short-interest ratio is presently 4.4 days. Currently, 5.8% of the company's stock are sold short. View Miragen Therapeutics' Current Options Chain.
Who are some of Miragen Therapeutics' key competitors?
Some companies that are related to Miragen Therapeutics include RadNet (RDNT), InVitae (NVTA), CareDx (CDNA), Veracyte (VCYT), Enzo Biochem (ENZ), Celcuity (CELC), PotNetwork (POTN), Psychemedics (PMD), Fulgent Genetics (FLGT), First Choice Healthcare Solutions (FCHS), Cancer Genetics (CGIX), Biocept (BIOC), OpGen (OPGN) and CBA Florida (CBAI).
Who are Miragen Therapeutics' key executives?
Miragen Therapeutics' management team includes the folowing people:
- Dr. William Stuart Marshall Ph.D., Co-Founder, Pres, CEO & Director (Age 54)
- Mr. Adam Scott Levy, Chief Bus. Officer (Age 40)
- Dr. Paul D. Rubin, Exec. VP of R&D (Age 64)
- Eric N. Olson, Co-Founder & Chairman of Scientific Advisory Board
- Dr. Michael R. Bristow, Co-Founder & Member of the Scientific Advisory Board (Age 73)
Has Miragen Therapeutics been receiving favorable news coverage?
News articles about MGEN stock have been trending somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Miragen Therapeutics earned a news impact score of 0.08 on Accern's scale. They also gave media headlines about the medical research company an impact score of 46.31 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
How do I buy shares of Miragen Therapeutics?
Shares of MGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Miragen Therapeutics' stock price today?
One share of MGEN stock can currently be purchased for approximately $7.16.
How big of a company is Miragen Therapeutics?
Miragen Therapeutics has a market capitalization of $221.61 million and generates $4 million in revenue each year. The medical research company earns $-26,510,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis. Miragen Therapeutics employs 65 workers across the globe.
How can I contact Miragen Therapeutics?
Miragen Therapeutics' mailing address is 6200 LOOKOUT ROAD, BOULDER CO, 80301. The medical research company can be reached via phone at 720-643-5200 or via email at [email protected]
MarketBeat Community Rating for Miragen Therapeutics (NASDAQ MGEN)
MarketBeat's community ratings are surveys of what our community members think about Miragen Therapeutics and other stocks. Vote "Outperform" if you believe MGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
